Our global sites Open Search About us Our science Our products Investors Sustainability Careers Get in touch Electronic communications Allergy Therapeutics PLC Shareholder services Electronic communications Overview At a glance Financial highlights Investment case Regulatory news Email alert Results, reports and presentations Financial Calendar Share tools Shareholder services AGM information Registrar Details Major shareholders Analyst coverage Electronic communications AIM Rule 26 Corporate governance Investor and Advisor Contacts Allergy Therapeutics has adopted electronic communications. This means that shareholders will receive documents from the Company electronically unless they elect to receive hard copies. All of the Group’s annual results and interim results will be published on this website. Please click here to view the financial reports . Shareholders can request hard copies of certain Company publications by contacting the Company.If you are a shareholder who has elected to receive hard copies of documents and you now wish to receive electronic communications, please contact our UK registrars, Link Asset Services on 0871 664 0300. Calls cost 12p per minute plus network extras. If telephoning from overseas, please dial +44 371 664 0300. Shareholders may revoke an election to receive electronic communications at any time. Click for top of the page Linkedin icon Quick links Head office General inquiries Terms and Conditions Privacy Statement Cookies Adverse Event Reporting Modern Slavery and Human Trafficking Statement Gender Pay Gap QCA Code Compliance statement Contact us Allergy Therapeutics, Dominion Way, Worthing, West Sussex, BN14 8SA, United Kingdom Tel +44 (0)1903 844 700 © Allergy Therapeutics 2021. By Emperor Cookie Control

Our global sites Open Search About us Our science Our products Investors Sustainability Careers Get in touch Our markets Allergy Therapeutics PLC Our markets Allergy Therapeutics continues to maintain a strong presence in Europe with established operations in 19 markets, either directly or via partnerships. Germany remains the Group’s main market, generating approximately 61% of the Group’s revenue in the 12 months ending 30 June 2019. In markets where we do not have a direct presence, we often make our products available through partners. The most important distributor markets for the Group are Canada, the Czech and Slovak Republics, South Korea, Greece and the Baltics. More recently, the Group has seen the granting of Market Authorisations in Berlarus and Serbia and the commencement of supply in Albania. Austria Germany Italy Netherlands Spain Switzerland UK Bencard Adjuvant Systems Allergy Therapeutics Plc Click for top of the page Linkedin icon Quick links Head office General inquiries Terms and Conditions Privacy Statement Cookies Adverse Event Reporting Modern Slavery and Human Trafficking Statement Gender Pay Gap QCA Code Compliance statement Contact us Allergy Therapeutics, Dominion Way, Worthing, West Sussex, BN14 8SA, United Kingdom Tel +44 (0)1903 844 700 © Allergy Therapeutics 2021. By Emperor Cookie Control